Daptomycin for Injection: Clinical Trials

2 trials of Daptomycin for Injection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1

Follow Daptomycin for Injection: new trials by email Literature Review of Daptomycin for Injection trials Research Report on Daptomycin for Injection

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Daptomycin for Injection - Bacteremia, Soft Tissue Infections
Phase 2CompletedMerck Sharp & Dohme LLC182018-12-062022-05-13
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
daptomycin, vancomycin - Endocarditis, Bacterial, Infective Endocarditis
Phase 2TerminatedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)382008-09-172018-12-24

Conditions studied

Bacteremia (2)  ·  Endocarditis (1)  ·  Endocarditis, Bacterial (1)  ·  Gram-Positive Bacterial Infections (1)  ·  Infections (1)  ·  Skin Diseases, Infectious (1)  ·  Soft Tissue Infections (1)  ·  Staphylococcal Infections (1)

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Merck Sharp & Dohme LLC (1)

Countries

Japan (1)  ·  United States (1)

Top investigators

Peter Pertel, MD (1)

Results publications

PMID 34920946